An observational, prospective study assessing the ncidence of cardiovascular events in patients with Chronic Myeloid Leukemia treated with Tyrosine Kinase Inhibitors
Latest Information Update: 12 Mar 2021
At a glance
- Drugs Bosutinib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary) ; Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 12 Mar 2021 New trial record
- 08 Mar 2021 Results published in the Acta Cardiologica